Phase II Trial of Erlotinib and Docetaxel in Advanced and Refractory Hepatocellular and Biliary Cancers: Hoosier Oncology Group GI06‐101 - Chiorean - 2012 - The Oncologist - Wiley Online Library


            
            

            

            




    	Skip to Article Content
	Skip to Article Information